


*Expand Your Options.
Surpass Your Expectations.*



AVAILABLE
IN **7.5 cm**
LENGTH

Flexible. Durable. Proven.



VIABAHN[®]
ENDOPROSTHESIS

HEPARIN
BIOACTIVE SURFACE

PERFORMANCE
through innovation

1 Flexible

Flexibility that expands treatment options to cover the most demanding anatomy.

- Conform to the anatomy of a moving arm
- Cross the elbow and flex angles > 90°

2 Durable

Durability that allows you to cover every curve.

- Utilize a kink-resistant design
- Apply trusted, proven materials
- No reported fractures crossing the elbow (Gore REVISE Clinical Study)

3 Proven

Proven clinical outcomes in the **only** stent-graft randomized, controlled study to investigate both stenotic and thrombotic occlusive AV Access patients (Gore REVISE Clinical Study).

- Re-establish flow to occluded grafts
- Increase patient's time to next intervention, safely

GORE REVISE CLINICAL STUDY OUTCOMES


Safe: GORE® VIABAHN® Endoprosthesis study group demonstrated non-inferiority in terms of freedom from major device, treatment, or procedure related adverse events as compared to the PTA group. ($p < 0.001$)

Effective: GORE® VIABAHN® Endoprosthesis study group demonstrated superiority in terms of target lesion primary patency as compared to the PTA group. ($p = 0.008$)

(See *Instructions for Use* for details)

GORE® VIABAHN®
Endoprosthesis in AV Access

GORE® VIABAHN® Endoprosthesis



W. L. GORE & ASSOCIATES, INC.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific) 800.437.8181 (United States)
00800.6334.4673 (Europe) 928.779.2771 (United States)

goremedical.com

Products listed may not be available in all markets.

GORE®, PERFORMANCE THROUGH INNOVATION, VIABAHN®, and designs are trademarks of W. L. Gore & Associates.

© 2013, 2016 W. L. Gore & Associates, Inc. AS0545-EN2 FEBRUARY 2016

INTENDED USE / INDICATIONS: The GORE® VIABAHN® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery de novo and restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 7.5 mm, in superficial femoral artery in-stent restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 6.5 mm, and in iliac artery lesions up to 80 mm in length with reference vessel diameters ranging from 4.0 – 12 mm. The GORE® VIABAHN® Endoprosthesis is also indicated for the treatment of stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access grafts. Refer to Instructions for Use at goremedical.com for a complete description of all contraindications, warnings, precautions and adverse events. ^{IX} Only